«The Experience of a Sore Mouth and Associated Symptoms in Patients With Cancer Receiving Outpatient Chemotherapy By: Brown, Carlton G. PhD, RN, AOCN; ...»
This research is in keeping with the newest Oncology Nursing Society Research Priorities wherein mucositis was ranked 20th in overall symptom importance.49 There is also a need for research that develops and tests intervention strategies focused on alleviating or preventing OM and its associated symptoms. In addition, more research is needed that investigates the consequences of OM, especially in the outpatient population where there is limited access to healthcare providers between chemotherapy treatments. Since the data are inconclusive on whether a particular gender experiences more severe OM, future prospective studies could be designed to detect gender specificity in relation to the impact of OM on overall patient quality of life. Finally, there is a need for studies that focus on the biological mechanisms underlying OM, including the role of proinflammatory cytokines and other substances in the development and interrelationships of OM and other symptoms such as fatigue, depression, and insomnia. Enhanced understanding of the pathobiology could ultimately lead to interventions designed to alleviate the burden associated with mucositis and other symptoms.
Finally, this study is one of the initial studies to examine selected consequences of an SM on oral intake, daily activity, time spent lying down, and the ability to work. The findings will hopefully stimulate further clinical research to delineate better assessment and management strategies for patients who have this challenging treatment-related adverse effect.
1. Dodd MJ, Larson PJ, Dibble SL, et al. Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Oncol Nurs Forum. 1996;23(6):921-927.
2. McGuire DB, Altomonte V, Peterson DE, Wingard JR, Jones RJ, Grochow LB. Patterns of mucositis and pain in patients receiving preparative chemotherapy and bone marrow transplantation. Oncol Nurs Forum.
3. Ped AM, Bellm LA, Epstein JB, Trotti A, Gwede C, Fuchs HJ. Complications of radiation therapy for head and neck cancers. Cancer Nurs. 2002;25(6):461-469.
4. Borbasi S, Cameron K, Quested B, Olver I, To B, Evans D. More than a sore mouth: patients' experience of oral mucositis. Oncol Nurs Forum. 2002;29(7):1051-1057.
5. Armstrong TS. Symptoms experience: a concept analysis. Oncol Nurs Forum. 2003;30(4):601-606.
6. Brown C, Beck S, Peterson D, McGuire D, Dudley W, Mooney K. Patterns of sore mouth in outpatients with cancer receiving chemotherapy. Support Care Cancer. 2009;17(4):413-428.
7. Rubenstein EB, Peterson DE, Schubert M, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004;100(9 suppl):2026-2046.
8. Peterson DE, Jones JB, Petit RG. Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer.
9. American Cancer Society. Mouth sores painful for patients: new scoring system to aid in treating mouth sores. http://www.cancer.org/docroot/NWS/content/NWS_1_1x_Mouth_Sores_Painful_for_Patients.asp.
Published July 19, 1999. Accessed December 9, 2008.
10. Woo SB, Sonis ST, Monopoli MM, Sonis AL. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer. 1993;72(5):1612-1617.
11. National Cancer Institute. Oral complications of chemotherapy and head and neck radiation.
http://www.cancer.gov/cancertopics/pdq/supportivecare/oralcomplications/healthprofessional. Updated 2008.
Accessed December 9, 2008.
12. Roemer J. An end to outpatient chemotherapy? Medicare takes aim at reimbursement. J Natl Cancer Inst.
13. Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy. clinical and economic outcomes of chemotherapy-induced mucositis. Cancer. 2003;98(7):1531-1539.
14. Miaskowski C, Dodd M, Lee K. Symptom clusters: the new frontier in symptom management research. J Natl Cancer Inst Monogr. 2004;(32):17-21.
15. Rutledge DM, McGuire C. Evidence-based symptom management. In: Yarbro CH, Frogge MH, Goodman M, eds. Cancer Symptom Management. 3rd ed. Sudbury, MA: Jones & Bartlett; 2003:3-14.
16. Dodd MJ, Miaskowski C, Paul SM. Symptom clusters and their effect on the functional status of patients with cancer. Oncol Nurs Forum. 2001;28(3):465-470.
17. National Institutes of Health. Symptom management in cancer: pain, depression and fatigue.
http://consensus.nih.gov/2002/2002CancerPainDepressionFatiguesos022html.htm. Updated 2002. Accessed December 9, 2008.
18. Kim H, McGuire DB, Tulman L, Barsevick AM. Symptom clusters: concept analysis and clinical implications for cancer nursing. Cancer Nurs. 2005;28(4):270-282. HTML Full Text
19. Elting LS, Shih YT. The economic burden of supportive care of cancer patients. Support Care Cancer.
20. Kolbinson DA, Schubert MM, Flournoy N, Truelove EL. Early oral changes following bone marrow transplantation. Oral Surg Oral Med Oral Pathol. 1988;66(1):130-138.
21. McGuire DB, Yeager KA, Dudley WN, et al. Acute oral pain and mucositis in bone marrow transplant and leukemia patients: data from a pilot study. Cancer Nurs. 1998;21(6):385-393. HTML Full Text
22. Peterson DE, Cariello A. Mucosal damage: a major risk factor for severe complications after cytotoxic therapy. Semin Oncol. 2004;31(3 suppl 8):35-44.
23. Keefe DMK, Gibson RJ, Hauer-Jensen M. Gastrointestinal mucositis. Semin Oncol Nurs. 2004;20(1):38-47.
24. Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100(9 suppl):1995-2025.
25. Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001;19(8):2201-2205.
26. Vokurka S, Bystrická E, Koza V, et al. Higher incidence of chemotherapy induced oral mucositis in females: a supplement of multivariate analysis to a randomized multicentre study. Support Care Cancer.
27. Zalcberg J, Kerr D, Seymour L, Palmer M. Haematological and non-haematological toxicity after 5fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Eur J Cancer. 1998;34(12):1871-1875.
28. Chiara S, Nobile NT, Sanguineti O, Cognein P, Rosso R. Oral mucositis in advanced colorectal cancer patients receiving continuous 5-fluorouracil (5-FU) infusions (c.i.)+oral leukovorin (L-LV). Support Care Cancer. 1996:238.
29. Raber-Durlacher JE, Weijl NI, Abu Saris M, de Koning B, Zwinderman AH, Osanto S. Oral mucositis in patients treated with chemotherapy for solid tumors: a retrospective analysis of 150 cases. Support Care Cancer.
30. Sonis S, Sonis A, Lieberman A. Oral complications in patients receiving treatment for malignancies other than of the head and neck. J Am Dent Assoc. 1978;97(3):468-472.
31. Eilers J, Berger AM, Peterson MC. Development, testing, and applications of the Oral Assessment Guide.
Oncol Nurs Forum. 1988;15:325.
32. Elting LS, Keefe DMK, Sonis ST. Treatment-Induced Gastrointestinal Toxicity in Patients With Cancer.
American Society of Clinical Oncology. Alexandria, VA; 2004:536-541.
33. Stiff P. Mucositis associated with stem cell transplantation: current status and innovative approaches to management. Bone Marrow Transplant. 2001;27 Suppl 2:S3-S11.
34. Scully C, Sonis S, Diz PD. Oral mucositis. Oral Dis. 2006;12(3):229-241. 10.1111/j.1601x.
35. American Cancer Society. Sore or irritated mouth or throat.
2008. Accessed December 9, 2008.
36. National Institute of Dental and Craniofacial Research. Chemotherapy and your mouth.
http://www.nidcr.nih.gov/OralHealth/Topics/CancerTreatment/ChemotherapyYourMouth.htm. Updated 2008.
Accessed December 9, 2008.
37. Cella DF, Jacobsen PB, Orav EJ, Holland JC, Silberfarb PM, Rafla S. A brief POMS measure of distress for cancer patients. J Chronic Dis. 1987;40(10):939-942.
38. Bellm LA, Cunningham G, Durnell L, et al. Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis: oral mucositis patient provider advisory board. Cancer Invest. 2002;20(5Magee T, Lee SM, Giuliano KK, Munro B. Generating new knowledge from existing data: The use of large data sets for nursing research. Nurs Res. 2006;55(2 suppl):S50-S56.
40. Mooney KH, Beck SL, Friedman RH, Farzanfar R. Telephone-linked care for cancer symptom monitoring:
a pilot study. Cancer Pract. 2002;10(3):147-154.
41. Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. Ann Acad Med Singapore.
42. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004;4(4):277-284.
43. Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer. 2003;97(11):2919-2925.
44. Wood LJ, Nail LM, Gilster A, Winters KA, Elsea CR. Cancer chemotherapy-related symptoms: evidence to suggest a role for proinflammatory cytokines. Oncol Nurs Forum. 2006;33(3):535-542.
45. Peterman A, Cella D, Glandon G, Dobrez D, Yount S. Mucositis in head and neck cancer: economic and quality-of-life outcomes. J Natl Inst Cancer Monogr. 2001;(29):45-51.
46. Francis DJ, Fletcher JM, Stuebing KK, Davidson KC, Thompson NM. Analysis of change: modeling individual growth. J Consult Clin Psychol. 1991;59(1):27-37.
47. Brown CG, McGuire DB, Beck SL, Peterson DE, Mooney KH. Visual graphical analysis: a technique to investigate symptom trajectories over time. Nurs Res. 2007;56(3):195-201. HTML Full Text
48. Peterson DE, Keefe DM, Hutchins RD, Schubert MM. Alimentary tract mucositis in cancer patients: impact of terminology and assessment on research and clinical practice. Support Care Cancer. 2006;14(6):499-504.
49. Doorenbos AZ, Berger AM, Brohard-Holbert C, et al. 2008 ONS research priorities survey. Oncol Nurs Forum. 2008;35(6):E100-E107.